Latest Commercial Agreements News

IODM Limited has secured a significant commercial agreement with Convera to provide its Connect platform to a major UK university, expected to add $600,000 annually from April 2026.

Structural Monitoring Systems Plc reports a profitable December quarter with 40% revenue growth, driven by strong avionics sales and progress toward FAA certification of its CVM™ technology.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Atomo Diagnostics has landed a significant $502,000 order for HIV self-tests destined for an African country, underscoring sustained demand for accessible diagnostics in the region.

Vitrafy Life Sciences has entered a 12-month exclusive partnership with IMV Technologies to integrate cryopreservation technologies, securing up to A$930k in fees and milestone payments.

Vitrafy Life Sciences has secured a 12-month exclusive partnership with global animal reproduction leader IMV Technologies to co-develop and commercialise next-generation cryopreservation solutions for farm animals and aquaculture.

White Energy’s subsidiary BCBC has clinched an exclusive global agency agreement with Komarek to market briquettor machines using its proprietary BCB technology starting January 2026. This deal extends White Energy’s foothold in coal upgrading amid evolving energy markets.

FlexiRoam has secured a key partnership to provide AI-enhanced connectivity for Malaysia’s national welfare initiative, supporting over 8 million recipients and marking a strategic step into mission-critical government infrastructure.

High-Tech Metals has signed a non-binding MoU with Wiluna Mining to assess toll treatment options for ore from its Mt Fisher and Mt Eureka projects, aiming to leverage existing processing infrastructure for capital-efficient development.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.